Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Oragens - AIM ImmunoTech

Drug Profile

Research programme: Oragens - AIM ImmunoTech

Alternative Names: Oragens; OragenTM0004

Latest Information Update: 05 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer AIM ImmunoTech
  • Class Adenine nucleotides; Oligonucleotides
  • Mechanism of Action Hepatitis B virus replication inhibitors; HIV replication inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis B; HIV infections; Solid tumours; Viral infections

Most Recent Events

  • 23 Aug 2019 Hemispherx Biopharma is now called AIM Immunotech
  • 19 Aug 2005 This programme is still in active development
  • 18 Sep 2003 Preclinical trials in Hepatitis B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top